Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-383 as a subcutaneous (SC) injection and intravenous (IV) infusion in Arm A and SC injections of ABBV-383 in Arm B. Around 55 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 25 sites across the world
In Arm A participants will receive one of two doses of ABBV-383 as an SC injection and (IV) infusions, during the 151 week study duration. In Arm B, participants will receive the selected dose from Arm A as SC injections, during the 151 week study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Start Date21 Jun 2024

Sponsor / Collaborator

AbbVie, Inc.

NCT06158841 / RecruitingPhase 3

A Phase 3, Multicenter, Randomized, Open Label Study of ABBV-383 Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of ABBV-383 compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM.
ABBV-383 is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. . In Arm A, participants will receive ABBV-383 as a monotherapy. In Arm B, participants will receive the standard available therapy (SAT) identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable. Around 380 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 140 sites across the world.
In Arm A participants will receive ABBV-383 as an infusion into the vein in 28 day cycles, during the 3.5 year study duration. In Arm B, participants will receive the SAT identified by the Investigator during screening, in accordance with the local (or applicable) approved label, package insert, summary of product characteristics, and/or the institutional guidelines, as applicable, during the 3.5 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Start Date09 May 2024

Sponsor / Collaborator

AbbVie, Inc.

NCT06158854 / RecruitingPhase 1/2

An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis

Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383.
ABBV-383 is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and safety expansion) with 5 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 doses. After completion of the dose escalation portion of the study, the safety expansion (part 2) portion of the study will begin. Two arms (arm 4-5) will begin and participants will receive 1 of 2 doses as determined during the dose escalation portion (part 1). Around 76 adult participants with relapsed/refractory AL amyloidosis will be enrolled at approximately 20 sites across the world.
Participants will receive ABBV-383 as an infusion into the vein for up to approximately 2 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Start Date01 Apr 2024

Sponsor / Collaborator

AbbVie, Inc.

100 Clinical Results associated with Etentamig

100 Translational Medicine associated with Etentamig

100 Patents (Medical) associated with Etentamig

Literatures (Medical) associated with Etentamig

02 Nov 2022·Cancer discovery

ABBV-383 Demonstrates Tolerability and Efficacy in Relapsed/Refractory MM

Article

Abstract:

The T cell–engaging bispecific antibody ABBV-383 was well tolerated in relapsed/refractory multiple myeloma (RRMM).

01 Nov 2022·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Article

Author: Kumar, Shaji ; Lee, Shane ; Bueno, Orlando F. ; Yue, Susan ; Rodriguez, Cesar ; Voorhees, Peter M. ; Vij, Ravi ; Freise, Kevin J. ; D'Souza, Anita ; Talati, Chetasi ; Weisel, Katja ; Jin, Ziyi ; Polepally, Akshanth R. ; Shah, Nina ; Buelow, Ben ; Ross, Jeremy A. ; Pothacamury, Rajvineeth K.

PURPOSE:

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study.

METHODS:

Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion.

RESULTS:

As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively.

CONCLUSION:

ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.

01 Jul 2020·EJHaem

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Article

Author: Leonidas, Marina ; Ndiaye, Ami ; Voorhees, Peter M. ; Rigby, Katherine ; Foureau, David M. ; Atrash, Shebli ; Buelow, Ben ; Symanowski, James T. ; Guo, Fei ; Paul, Barry A. ; Tjaden, Elise ; Bhutani, Manisha ; Robinson, Myra ; Pham, Duy ; Steuerwald, Nury ; Usmani, Saad Z.

Abstract:

TNB‐383B is a fully human BCMA‐targeting T‐cell engaging bispecific monoclonal antibody (T‐BsAb). We assessed ex vivo efficacy of this drug to mediate killing of bone marrow mononuclear cells (BMMCs) freshly isolated from 10 patients with relapsed multiple myeloma (MM). BMMC were treated ex vivo with TNB‐383B at doses ranging from 0.001‐1 μg. Plasma cell (PC) lysis, viability, BCMA expression, CTL distribution, and degranulation were assessed by flow cytometry. Cytokine response to TNB‐383B was quantified by multiplex protein assay. Dose‐dependent PC lysis was triggered in all cases by TNB‐383B at doses as low as 0.001 μg (P = .0102). Primary MM cells varied in BCMA expression. High BCMA+ PC count correlated with increased PC lysis (P = .005) and significant CTL degranulation specific to TNB‐383B treatment (P = .0153 at 1 μg). High E:T ratio in bone marrow specimens led to lower viable and higher apoptotic PC compared with low E:T ratio (P < .001). Three cytokines were significantly modulated by TNB‐383B: IL‐2/TNFα increased by ∼4 ± 3.5‐fold average (P < .005 at 1 μg) and IP10 increased by ∼50 ± 15‐fold (P < .001 at 1 μg). We conclude that TNB‐383B triggers primary PC lysis and CTL degranulation in a dose‐dependent fashion ex vivo with no T cell expansion and mild increase of CRS‐associated cytokines.

News (Medical) associated with Etentamig

05 Jun 2024

·www.prnewswire.com

AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available therapies (SATs) in patients with r/r MM who have received at least two lines of prior therapy NORTH CHICAGO, Ill., June 5, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.1 ABBV-383 is being evaluated in a Phase 3, multicenter, randomized, open-label study compared with standard available therapies in patients with r/r MM who received at least two lines of prior therapy. "Despite notable advances in treatment, most patients with multiple myeloma will eventually relapse. Patients with advanced disease, especially in the community setting, often have limited access to novel treatment options and existing options have a high treatment burden, including frequent dosing," said Dr. Peter Voorhees, clinical professor of medicine, director of plasma cell disorders, Atrium Health Levine Cancer Institute. "The CERVINO Phase 3 trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing and we look forward to seeing the data as it emerges." Multiple myeloma is a blood cancer characterized by abnormal proliferation of plasma cells, which can cause end-organ damage and is the second most commonly occurring blood cancer in the world.2 An estimated 176,000 people globally were diagnosed with multiple myeloma in 2020, and 117,000 people died from the disease.3 "The start of the CERVINO Phase 3 trial marks an important step forward in AbbVie's continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients," said Mariana Cota Stirner, M.D., vice president, therapeutic area head oncology, hematology, AbbVie. "ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximizing treatment simplicity for physicians and patients, if proven in the clinical trials." About the CERVINO Study CERVINO (NCT06158841) is a global, Phase 3, multicenter, randomized, open-label, parallel-group study evaluating ABBV-383 in adult patients (≥18 years) with r/r MM and an Eastern Cooperative Oncology Group performance status ≤2 who received at least two prior lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 mAb. Patients who received prior BCMA-targeted therapy will be excluded. Patients will be randomized 1:1 to receive intravenous ABBV-383 60mg Q4W or the investigator's choice of SAT (carfilzomib + dexamethasone, elotuzumab + pomalidomide + dexamethasone, or selinexor + bortezomib + dexamethasone), and will continue treatment until confirmed progressive disease or other discontinuation criteria are met. The dual primary end points are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR) or better, very good partial response or better, rate of minimum residual disease negativity, and change in disease symptoms and physical functioning. Approximately 140 sites globally will enroll approximately 380 total patients. Additional information about the study can be found at under the identifier NCT06158841. About ABBV-383 ABBV-383 is an investigational distinctive BCMA x CD3 bispecific antibody T-cell engager composed of bivalent high-avidity BCMA-binding domains, a low-affinity CD3-binding domain designed to reduce cytokine release, and a silenced Fc tail designed for an extended half-life that may support once every 4-week (Q4W) dosing. Clinical relevance of these structure activity relationships has not been established. BCMA is highly expressed on the surface of malignant plasma cells in multiple myeloma, making it an ideal target for therapy. BCMA plays a crucial role in the survival of myeloma cells by promoting their growth and inhibiting their apoptosis (programmed cell death).4 About AbbVie in Oncology At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, and bi-specific and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio is comprised of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit us at . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 1 Foureau DM, Bhutani M, Robinson M, et al: Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma. EJHaem 1:113-121, 2020 2 International Myeloma Foundation. What is Multiple Myeloma? 3 Cancer.Net. Multiple Myeloma: Statistics. . 4 Cho SF, Anderson KC, Tai YT: Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol 9:1821, 2018 SOURCE AbbVie

Phase 3ImmunotherapyASCO

05 Jun 2024

·www.biopharmadive.com

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the National Institutes of Health that you may have missed from earlier this week.Eli Lillys drug tirzepatide sold as Zepbound for obesity continues to show promise in the liver disease MASH. Clinical trial data disclosed in an abstract ahead of a European medical conference indicates that, after one year, the shot helped improve liver fibrosis without worsening MASH in just over half of treated participants, compared with 30% of those given placebo. Lilly had hinted at the studys success earlier this year, but the full data will provide a more complete view of tirzepatides potential. The abstracts release comes one day after Viking Therapeutics released trial datafor its MASH pill VK2809 and less than two months after Madrigal Pharmaceuticals won U.S. approval of the first MASH drug. Madrigal shares fell Wednesday morning, as did those of several other MASH drug developers. Jonathan GardnerCytokinetics CEO Robert Blum confirmed the biotechnology company held sale talks late last year, as was reported around then by The Wall Street Journal and Reuters. In comments at a conference hosted by the investment bank Jefferies Wednesday, he said Cytokinetics engaged in good faith negotiations with an unnamed third party regarding an acquisition. While Cytokinetics board was supportive of proceeding with discussions on substantially the terms the counterparty communicated, that company ultimately did not move forward with an acquisition. Ned PagliaruloGilead Sciences has reached an agreement to settle federal lawsuits alleging the company delayed introducing an antiviral treatment so that it could extend patent protection for its HIV drug business. The company, which has not admitted liability or wrongdoing, will pay up to $40 million to a group of approximately 2,625 plaintiffs, provided 98% agree to the settlement. Litigation in California on this same issue, which involves two forms of the HIV drug tenofovir, remains pending at the states supreme court. Ned PagliaruloAbbVie said Wednesday it has enrolled the first patient in a Phase 3 trial of its dual-acting antibody ABBV-383 for multiple myeloma. ABBV-383 binds to a protein flag called BCMA on diseased cells and another called CD3 on T cells to spur an immune attack on the blood cancer. The mechanism is similar to that of the approved drugs from Johnson & Johnson and Pfizer. AbbVies trial will enroll 380 people whose disease has progressed after at least two lines of therapy. Patients will receive either ABBV-383 or another combination therapy. Researchers will follow patients to assess treatment responses and whether AbbVies drug helps stave off cancer progression better than the comparator treatments. Jonathan GardnerTwo clinical trials will test Gilead Sciences long-acting HIV drug lencapavir as preventive therapy in cisgender women and in people who inject drugs. The studies, which are funded by Gilead and run through the HIV Prevention Trials Network, will test whether twice-yearly injections of lencapavir works better as pre-exposure prophylaxis than an existing regimen. Cisgender women and injectable drug users have been underrepresented in studies of HIV treatment, according to a statement from the National Institutes of Health, which provides grants to the trials network. Ned Pagliarulo '

Phase 3AcquisitionClinical StudyDrug Approval

21 Feb 2024

·firstwordpharma.com

FDA priority review moves Regeneron closer to myeloma nod for BCMA-targeting bispecific

The FDA has granted Regeneron Pharmaceuticals' bispecific antibody linvoseltamab a priority review to treat fourth-line patients with relapsed/refractory multiple myeloma (MM). However, while early studies suggest the BCMAxCD3 antibody may be effective, doubts remain about its ability to stand out in an increasingly crowded field of treatment options.These include other BCMAxCD3 bispecifics already on the market such as Johnson & Johnson's Tecvayli (teclistamab-cqyv) and Pfizer's Elrexfio (elranatamab-bcmm), as well as experimental candidates like AbbVie's ABBV-383, a drug in the same class (for more, see KOL Views Q&A: Leading MM specialist discusses outlook for new bispecifics from J&J, Pfizer).Regeneron's filing is backed by data from the Phase I/II LINKER-MM1 trial showing an objective response rate of 71% among patients who got the recommended 200mg dose of linvoseltamab, including 46% who had a complete response or better. After a minimum of 24 weeks of therapy, those who achieved a very good partial response or better shifted from every two-week to every four-week dosing.All patients treated with the 200mg dose experienced an adverse event (AE), including 85% who with a Grade ≥3 AE. The most common AE was cytokine release syndrome (CRS), which was reported at 46%, with the vast majority deemed to be Grade 1 or 2 cases.Promising, but indistinguishable agents?Key opinion leaders (KOLs) interviewed for a FirstWord report agreed that early data for linvoseltamab as well as for ABBV-383 appear promising, although there seems to be little to distinguish either of these agents from each other or from Tecvayli and Elrexfio. They suggested ABBV-383, which is in Phase I testing for fourth-line MM, could hold an advantage over linvoseltamab due to a less frequent dosing schedule and subcutaneous delivery, compared with the need for intravenous infusions with Regeneron's drug.European regulators have also recently accepted linvoseltamab for review. The clinical development programme for the drug includes the confirmatory Phase III trial LINKER-MM3 trial in patients with relapse/refractory MM. The study is currently enrolling and is expected to read out in 2032.Regeneron is also testing it for earlier use, including in a Phase I/II trial in the first-line setting, a Phase II trial in high-risk smoldering MM and a Phase II trial in monoclonal gammopathy of undetermined significance. Planning for a Phase I study of linvoseltamab plus one of Regeneron's CD38xCD28 costimulatory bispecifics is also in the works.

Phase 1Phase 2Phase 3Priority ReviewClinical Result

100 Deals associated with Etentamig

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 3	IL	AbbVie, Inc.	09 May 2024
Multiple Myeloma	Phase 3	TW	AbbVie, Inc.	09 May 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	US	AbbVie, Inc.	01 Apr 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	JP	AbbVie, Inc.	01 Apr 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	AU	AbbVie, Inc.	01 Apr 2024
Plasma cell myeloma refractory	Phase 2	US	TeneoOne, Inc.	24 Jun 2019
Plasma cell myeloma refractory	Phase 2	DE	TeneoOne, Inc.	24 Jun 2019
Relapse multiple myeloma	Phase 2	US	TeneoOne, Inc.	24 Jun 2019
Relapse multiple myeloma	Phase 2	DE	TeneoOne, Inc.	24 Jun 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03933735 (NCT03933735, ASCO2024)	Phase 1	Relapse multiple myeloma sBCMA \| IL-6 \| IL-8 ... View more	-	ABBV-383 20 mg Q3W	tvtmrcuezf(yaoswwjljb) = 89% reduction of CD8+ T cells from periphery nogldtnvkv (bdmxpwbrth ) View more	Positive	24 May 2024
				ABBV-383 40 mg Q3W
NCT03933735 (NCT03933735, ASCO2024)	Phase 1	Relapse multiple myeloma	220	ABBV-383 60mg Q4W	tiwyyipalf(qfhoplsgmf) = etrjilaixb neoxhwoeam (jqgiymqeqc ) View more	Positive	24 May 2024
				ABBV-383 40mg Q3W	tiwyyipalf(qfhoplsgmf) = ndwafjscmr neoxhwoeam (jqgiymqeqc ) View more
NCT03933735 (NCT06158841, ASCO2024)	Phase 1	Relapse multiple myeloma BCMA- \| CD3	220	ABBV-383 20 mg Q3W	aasobbmunb(amhjqqybbz) = clqlxrckgm ewqotspqyg (dacwburudu ) View more	Positive	24 May 2024
				ABBV-383 40 mg Q3W	aasobbmunb(amhjqqybbz) = ibidjkejps ewqotspqyg (dacwburudu ) View more
NCT03933735 (phase 1 trial, EHA2024)	Phase 1	Relapse multiple myeloma BCMA \| CD3	220	ABBV-383 60mg Q4W	lvcnemidll(gfgzubdxel) = zoygwkwopr wwoxuaqows (zzuibzvvtt ) View more	Positive	14 May 2024
				ABBV-383 40mg Q3W	lvcnemidll(gfgzubdxel) = chvbgzubfd wwoxuaqows (zzuibzvvtt ) View more
IMS2023	Phase 1	Relapse multiple myeloma BCMA-positive \| CD3	-	ABBV-383	zmxlyrjlnq(bfnexdfvzn) = anemia (29%) klxllywios (njkdpqaemh ) View more	-	26 Sep 2023
NCT03933735 (Pubmed) Manual	Phase 1	Relapse multiple myeloma Last line	128	ABBV-383 (ESC+EXP)	pwsseofvww(vimewrnrqy) = famszmzoby qyvokttkhi (scznlpirin ) View more	Positive	27 Aug 2022
				ABBV-383 (EXP)	pwsseofvww(vimewrnrqy) = mtnoywvwga qyvokttkhi (scznlpirin ) View more
NCT03933735 (IMS2022)	Phase 1	Relapse multiple myeloma	124	ABBV-383	lvuqrlnezy(aszsjwulrd) = Among pts treated at 60mg (n=60; ESC+EXP), CRS occurred in 72% of the pts (48% G1; 22% G2; 2% G3) with the first dose, with median time to onset and resolution of 1 day (0% recurrence). Other AEs observed in >20% of all pts are fatigue (30%; G3-4, 1%), anemia (29%; G3-4, 16%), nausea (29%; G3-4, 2%), diarrhea (27%; G3-4, 2%), vomiting (24%; G3-4, 0%), and neutrophil count decreased (22%; G3-4, 19%) yxwbrdzagq (xppqvhooxs ) View more	-	25 Aug 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Etentamig

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation